antisens
oligonucleotid
aso
small
interf
rna
sirna
promis
specif
correct
diseasecaus
gene
express
therapeut
implement
howev
forestal
poor
deliveri
appropri
tissu
cell
type
subcellular
compart
topic
administr
consid
circumv
issu
avail
inhal
devic
unmet
medic
need
lung
diseas
focus
effort
tissu
report
develop
novel
cell
sort
method
quantit
cell
typespecif
analysi
sirna
lock
nucleic
acid
lna
aso
uptak
efficaci
intratrach
administr
mice
fluoresc
dye
label
compar
util
approach
whole
anim
whole
tissu
analysi
examin
extent
tissu
distribut
detail
rapid
system
access
renal
clearanc
therapeut
class
lack
efficaci
protein
level
lung
macrophag
epithelia
cell
type
nevertheless
observ
effici
redirect
administ
phosphorothio
ps
lna
aso
liver
kidney
lead
target
gene
knockdown
data
suggest
deliveri
remain
key
obstacl
topic
administ
nake
oligonucleotid
efficaci
lung
introduc
inhal
potenti
viabl
altern
inject
antisens
administr
liver
kidney
throughout
turbul
histori
oligonucleotid
therapeut
face
two
major
problem
lack
tissu
target
ineffici
cellular
uptak
present
believ
insignific
lung
diseas
applic
lung
epithelia
macrophag
directli
access
inhal
moreov
constitut
primari
entri
point
respiratori
virus
contribut
substanti
underli
inflamm
asthma
chronic
obstruct
pulmonari
diseas
thu
clinic
util
classic
antisens
oligonucleotid
aso
small
interf
rna
sirna
inhal
therapeut
intens
investig
notabl
whilst
advanc
aso
candid
util
chemic
modif
impart
stabil
phosphorothio
ps
backbon
nucleosid
sirna
equival
gener
unmodifi
molecul
phosphodiest
backbon
po
perplexingli
preclin
report
efficaci
contradictori
tissu
distribut
cell
typespecif
uptak
extent
durat
activ
well
immunestimulatori
potenti
matter
address
number
differ
anim
model
diseas
across
rodent
primat
speci
result
appear
mix
gener
attribut
differ
experiment
design
gener
accept
efficaci
deliveri
system
might
advantag
recent
lock
nucleic
acid
lna
contain
aso
shown
deliv
liver
nonhuman
primat
remark
efficaci
follow
parenter
administr
use
lna
result
substanti
increas
asobind
effici
target
improv
efficaci
consequ
consider
shorter
aso
use
equival
specif
classic
nucleotid
long
aso
moreov
potenc
vivo
report
compar
better
sirna
without
requir
deliveri
modif
formul
studi
multipl
cell
line
indic
least
vitro
phenomenon
replic
absenc
result
oligonucleotid
activ
lung
far
report
whole
tissu
level
howev
number
studi
indic
variabl
uptak
label
oligo
efficaci
measur
averag
achiev
across
differenti
transfect
lung
cell
type
directli
address
develop
tissu
disrupt
cell
sort
method
tdc
isol
diseaserelev
cell
downstream
analysi
focus
epitheli
cell
macrophag
two
import
target
cell
lung
diseas
fresh
mous
lung
tissu
disrupt
use
mechan
enzymat
approach
yield
singlecel
suspens
suspens
treat
magnet
bead
separ
andor
fluorescentactiv
cell
sort
obtain
popul
live
epitheli
cell
macrophag
remain
cell
type
supplementari
figur
next
carri
pilot
studi
luciferaseexpress
transgen
mice
establish
statist
power
success
measur
knockdown
luminometri
carri
whole
bodi
whole
tissu
mix
cell
cell
typespecif
level
n
wherea
whole
bodi
bioluminesc
consider
variabl
lung
liver
tissu
bioluminesc
surprisingli
consist
supplementari
figur
nevertheless
minimum
seven
anim
per
group
found
necessari
achiev
power
tissu
level
oneor
twosid
ttest
tdc
luminometri
measur
howev
enabl
reduct
anim
use
tabl
three
anim
per
experiment
group
calcul
suffici
reveal
knockdown
power
compar
util
topic
administ
lna
aso
sirna
anim
dose
intratrach
sequenc
luciferas
lung
collect
hour
postadministr
disappointingli
neither
class
oligonucleotid
achiev
knockdown
luciferas
across
lung
cell
type
figur
furthermor
mass
spectrometri
analysi
tdc
prepar
reveal
pslna
oligo
retain
lung
cell
macrophag
unexpectedli
substanti
proport
pslna
dose
detect
liver
hour
dose
respect
interestingli
kidney
also
accumul
substanti
quantiti
hour
respect
load
oligo
per
gram
tissu
figur
fate
polna
sirna
remain
elus
find
put
question
number
theori
lung
util
activ
sirna
therefor
decid
examin
fate
differ
class
oligo
administr
use
sulphon
dye
molecular
beacon
curiou
role
lung
surfact
lung
cell
uptak
sirna
impact
cation
charg
aggreg
anion
oligonucleotid
toward
hypothes
situ
particl
format
lung
lumen
decid
examin
lung
tissu
across
multipl
time
point
strikingli
even
minut
administr
urin
excret
observ
indic
rapid
absorpt
lung
classic
fight
flight
respons
handl
result
emict
anim
urin
dye
control
sirna
polnatr
anim
blue
color
like
account
dark
blue
color
sulphon
dye
confirm
mass
spectrometri
analysi
grouppool
urin
sampl
supplementari
figur
moreov
sulphon
sirna
antisens
sequenc
polna
present
urin
sampl
higher
concentr
measur
pslna
indic
greater
retent
pslna
within
system
supplementari
tabl
fluoresc
imag
excis
fix
lung
tissu
indic
hour
pslna
follow
polna
retain
lung
protract
fashion
wherea
sirna
undetect
figur
b
imag
entir
anim
hour
postdos
identifi
urinari
bladder
distinct
locat
sirna
concentr
importantli
stark
contrast
substanti
quantiti
pslna
still
circul
figur
data
reaffirm
function
observ
obtain
unlabel
materi
indic
inhal
sirna
po
ps
oligo
rapidli
escap
lung
via
system
circul
sirna
po
oligo
dose
renal
excret
potenti
matter
minut
explor
mechan
system
access
lung
lumen
carri
histolog
studi
sulphon
oligo
hematoxylin
eosin
stain
b
document
absenc
appreci
lymphocyt
infiltr
supplementari
figur
confoc
imag
formalin
fix
paraffin
embed
section
reaffirm
notion
rapid
po
oligo
clearanc
pslna
uniformli
detect
section
across
lung
lobe
figur
wherea
sirna
signal
detect
weak
polna
signal
observ
scatter
lung
macrophag
figur
examin
subcellular
local
pslna
minut
indic
presenc
discreet
particul
structur
within
macrophag
alveolar
epithelia
bronchial
epithelia
endothelia
figur
moreov
diffus
submucos
fiber
stain
also
detect
larger
airway
interestingli
particul
structur
observ
lung
lumen
challeng
surfact
oligo
interact
hypothesi
altern
lumin
resid
time
particl
might
substanti
minut
extracellular
complex
could
lost
prepar
formalin
fix
paraffin
embed
section
hour
accumul
oligo
enhanc
alveolar
macrophag
cell
reminisc
type
ii
alveolar
epithelia
suggest
ongo
uptak
accumul
deep
lung
interestingli
membran
spread
type
cell
bronchial
distribut
remain
similar
supplementari
figur
hour
diffus
cytosol
stain
observ
scatter
bronchial
epithelia
wherea
major
oligo
appear
associ
submucos
membran
elastin
fiber
supplementari
figur
collect
data
indic
administ
pslna
sirna
polna
abl
enter
lung
cell
effici
manner
form
discreet
intracellular
structur
follow
intern
yet
unabl
mediat
target
gene
knockdown
distinct
lack
nuclear
local
pslna
across
time
point
studi
accord
recent
vitroderiv
proposit
might
requir
efficaci
curious
type
ii
alveolar
epithelium
cell
line
indic
exhibit
similar
pslna
aso
uptak
pattern
gymnot
experi
vitro
equal
refractori
targetspecif
knockdown
observ
data
studi
support
earli
report
vitroin
vivo
correl
efficaci
gymnot
experi
howev
extent
nuclear
cytosol
accumul
univers
necessari
phenomenon
celltyp
specif
requir
remain
determin
natur
intracellular
punctuat
structur
form
pslna
vivo
studi
subject
ongo
investig
though
earli
attempt
fail
find
coloc
wellestablish
marker
earli
endosom
caveosom
caveolin
previou
report
system
pharmacokinet
administ
ps
aso
observ
liver
load
pslna
aso
disappoint
perform
inhal
oligo
lung
encourag
us
investig
util
noninvas
rout
pslna
aso
deliveri
liver
initi
mice
dose
intraven
iv
known
oligo
apolipoprotein
b
apob
necropsi
perform
time
point
provid
kinet
profil
knockdown
liver
signific
knockdown
p
achiev
singl
dose
maxim
effect
achiev
hour
maintain
day
hour
figur
variabl
within
neg
control
group
consist
normal
behavior
gene
express
possibl
driven
circadian
rhythm
feed
pattern
due
high
potenc
exhibit
vivo
comparison
iv
administr
perform
lower
dose
anim
sacrif
variou
time
point
provid
kinet
insight
knockdown
target
figur
knockdown
achiev
use
either
administr
rout
hour
compar
vehicl
treatment
figur
overal
dose
apob
pslna
attain
exposur
observ
liver
kidney
respect
compar
iv
dose
figur
demonstr
appreci
amount
pslna
aso
enter
liver
dose
case
suffici
drive
signific
knockdown
target
mrna
notabl
time
maxim
effect
delay
dose
group
figur
like
due
protract
absorpt
lung
system
circul
slow
time
maxim
liver
concentr
howev
upon
chronic
weekli
administr
would
expect
clinic
small
imped
would
expect
insignific
collect
data
demonstr
direct
administr
lung
sirna
polna
readili
taken
lung
cell
instead
rapidli
absorb
renal
clear
thu
accuraci
earli
report
efficaci
topic
sirna
administr
lung
challeng
studi
examin
util
liposom
polymer
deliveri
system
improv
topic
administr
efficaci
put
question
inde
increas
evid
amass
innat
immun
activ
might
account
numer
group
interpret
rna
interfer
strike
demonstr
power
respons
deliv
studi
indic
sirna
mild
tolllik
receptor
agonist
intraperiton
dose
tolllik
receptor
activ
shown
suppress
choroid
neovascular
rodent
eye
elsewher
sirnamedi
tolllik
receptor
activ
shown
respons
curtail
viral
infect
includ
instanc
previous
report
ontarget
rna
interfer
pulmonari
viral
infect
model
taken
togeth
data
suggest
sirna
administ
topic
lung
either
intranas
without
form
deliveri
enhanc
deliv
lung
cell
enact
rna
interfer
nonetheless
caution
extrapol
find
primat
speci
larger
ps
aso
molecul
claim
efficaci
follow
topic
administr
lung
lung
rather
view
bodi
evid
make
strong
case
examin
close
inhal
oligonucleotid
fate
clinic
relev
speci
man
robustli
underpin
proof
mechan
conclus
importantli
stark
contrast
polna
sirna
pslna
aso
appear
retain
lung
epithelia
though
appreci
amount
oligo
detect
mass
spectrometri
macrophag
knowledg
first
report
subcellular
local
inhal
oligo
lung
across
multipl
time
point
earli
minut
dose
understand
entri
mechan
traffick
pslna
variou
cell
type
lung
undoubtedli
import
address
lack
efficaci
document
studi
crucial
despit
observ
retent
pslna
aso
lung
oligo
also
inact
diseaserelev
cell
type
suggest
efficaci
lung
issu
stabil
issu
deliveri
howev
pslna
aso
also
access
system
circul
appreci
durat
taken
liver
exhibit
knockdown
liver
mrna
target
result
indic
inhal
approach
might
util
system
target
oligonucleotid
therapeut
aptam
circulatori
endotheli
target
liverand
kidneytarget
antisens
therapi
clinic
relev
evalu
longterm
impact
lung
administr
howev
necessari
wherea
alveolar
macrophag
observ
perform
welldocu
role
detritu
clearanc
deep
lung
accumul
type
ii
alveolar
epitheli
precursor
resid
lung
stem
cell
indic
intracellular
bodi
observ
studi
outcom
serendipit
interact
membran
protein
phenomenon
might
prove
sequencespecif
ultim
inconsequenti
conclus
report
novel
tdc
techniqu
enabl
conclus
demonstr
lack
sirna
lna
asomedi
activ
either
macrophag
epithelia
mous
lung
topic
administr
nonphosphorothio
oligo
partit
rapidli
system
circul
elimin
via
renal
rout
within
minut
use
ps
backbon
lna
aso
result
appreci
lung
macrophag
accumul
demonstr
activ
histolog
examin
demonstr
whilst
tissu
penetr
lung
ubiquit
rapid
transport
mechan
might
account
system
access
crucial
pslna
aso
rel
refractori
rapid
renal
clearanc
suffici
amount
lungabsorb
oligo
remain
circul
accumul
substanti
quantiti
liver
kidney
case
apobtarget
oligonucleotid
amount
drug
absorb
lung
suffici
accumul
liver
pharmacolog
activ
level
lead
knockdown
apob
mrna
thu
report
pioneer
prospect
noninvas
administr
oligonucleotid
therapeut
circulatori
liver
kidney
diseas
oligonucleotid
screen
vitro
supplementari
materi
method
collect
custom
design
sirna
lna
aso
eurogentec
southampton
uk
target
luciferas
identifi
sequenc
tabl
ic
valu
nmoll
nmoll
posttransfect
gymnot
uptak
respect
hour
signific
cytotox
observ
mismatch
control
sirna
mmsirna
pslna
mmpslna
design
yield
appreci
activ
detect
ic
previous
describ
pslna
aso
apob
gymnot
ic
nmoll
use
liver
efficaci
studi
quantif
oligonucleotid
uptak
cell
tissu
perform
mass
spectrometri
supplementari
materi
method
anim
model
asthma
chronic
obstruct
pulmonari
diseas
focu
innat
immun
activ
pathway
relat
biomark
measur
efficaci
sirna
carri
risk
activ
wherea
lna
aso
current
believ
refractori
immunostimul
minim
confound
impact
potenti
oligonucleotidemedi
immun
activ
perform
studi
report
mice
express
luciferas
constitut
control
pro
lung
dissoci
use
collagenasednas
enzym
mix
gentlemac
tissu
dissoci
miltenyi
biotec
woke
uk
remain
red
blood
cell
remov
hemolysi
describ
supplementari
materi
method
section
mous
lung
cell
suspens
prepar
sort
separ
macrophag
epitheli
cell
describ
supplementari
materi
method
section
ex
vivo
luminometri
luciferas
activ
proport
enzym
concentr
protein
report
halflif
vivo
enabl
luminometri
measur
marker
knockdown
effici
thu
assay
perform
tdc
prep
white
microtitr
plate
matrix
loughborough
uk
cell
centrifug
minut
supernat
discard
ml
room
temperatur
dpb
ca
mg
sigma
dorset
uk
ad
ml
roomtemperatur
britelit
plu
reagent
perkin
elmer
waltham
ad
plate
immedi
read
envis
plate
reader
use
standard
ultrasensit
luminesc
protocol
sec
read
per
well
probe
distanc
well
luminesc
express
rel
light
unit
follow
background
substract
threshold
rel
light
unit
determin
maintain
linear
consist
detect
supplementari
figur
thu
set
requir
cell
number
mix
cell
macrophag
epithelia
cell
type
appreci
loss
viabil
bioluminesc
activ
observ
tdc
perform
hour
fresh
tissu
excis
storag
fetal
bovin
serumsuppl
dpb
lung
deliveri
studi
use
sulphon
oligo
fluoresc
imag
sulphon
oligo
supplementari
materi
method
anim
tissu
carri
use
ivisspectrum
excit
set
nm
monitor
emiss
nm
whole
anim
imag
carri
hour
dose
mild
inhal
isofluoran
anesthesia
lung
remov
design
time
hour
follow
dose
right
lung
lobe
flash
frozen
liquid
nitrogen
left
lung
lobe
inflat
fix
neutralbuff
formalin
hour
fixat
lung
place
plate
imag
describ
region
interest
drawn
around
lung
total
fluoresc
measur
photonsecond
confoc
microscopi
dapi
stain
carri
immedi
imag
specimen
imag
invert
confoc
microscop
leica
tc
leica
microsystem
milton
keyn
uk
use
len
leica
hcx
pl
apo
cs
oil
uv
imag
blue
dapi
green
autofluoresc
far
red
channel
taken
sequenti
mode
use
appropri
excit
emiss
set
imag
whole
lung
section
assembl
high
resolut
imag
cover
whole
area
section
use
leica
tile
algorithm
leica
maximum
project
zstack
space
cover
height
entir
section
use
qualit
assess
label
distribut
across
section
ex
vivo
luminometri
studi
perform
either
pilot
studi
five
anim
per
group
nonparametr
twosid
mannwhitney
utest
perform
liver
efficaci
studi
due
small
sampl
size
n
per
group
comparison
consid
statist
signific
p
data
analyz
graph
use
graphpad
prism
softwar
version
supplementari
materi
figur
applic
tdc
result
highli
consist
luminesc
readout
figur
character
pneumonocyt
prepar
tdc
figur
extract
ion
chromatogram
oligo
figur
lung
histolog
confirm
lack
lymphocyt
infiltr
consequ
intratrach
oligonucleotid
administr
figur
confoc
imagin
intratrach
administ
phosphorothio
lna
antisens
pslna
distribut
mous
lung
time
figur
linear
luminesc
luciferas
transgen
mous
lung
cell
ex
vivo
figur
stabil
assess
sirna
use
lcmsm
tabl
oligo
detect
ms
urin
sampl
materi
method
